• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

C4 Therapeutics, Inc. - Common Stock (NQ: CCCC )

3.950 +0.100 (+2.60%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 4,578,545
Open 3.780
Bid (Size) 3.820 (1)
Ask (Size) 3.970 (5)
Prev. Close 3.850
Today's Range 3.720 - 3.980
52wk Range 3.610 - 11.88
Shares Outstanding 48,797,226
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
AT&T To Rally More Than 33%? Here Are 10 Top Analyst Forecasts For Thursday
December 19, 2024
Via Benzinga
C4 Therapeutics Presents Cemsidomide Phase 1 Data at the American Society for Hematology (ASH) Annual Meeting that Demonstrated Potential to Become Best-in-Class IKZF1/3 Degrader
December 08, 2024
From C4 Therapeutics, Inc.
Via GlobeNewswire

Performance

YTD
-39.42%
-39.42%
1 Month
-1.50%
-1.50%
3 Month
-35.98%
-35.98%
6 Month
-16.14%
-16.14%
1 Year
-11.43%
-11.43%

More News

Read More
C4 Therapeutics Appoints Accomplished Oncology Executive Steve Hoerter to Board of Directors
November 20, 2024
From C4 Therapeutics, Inc.
Via GlobeNewswire
C4 Therapeutics Announces First Patient Dosed in CFT8919 Clinical Trial
November 06, 2024
From C4 Therapeutics, Inc.
Via GlobeNewswire
Key Takeaways From C4 Therapeutics Analyst Ratings
May 09, 2024
Via Benzinga
C4 Therapeutics to Present Data from the Ongoing Phase 1/2 Trial of Cemsidomide in Multiple Myeloma and Non-Hodgkin’s Lymphoma at the American Society of Hematology (ASH) Annual Meeting
November 05, 2024
From C4 Therapeutics, Inc.
Via GlobeNewswire
C4 Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
October 31, 2024
From C4 Therapeutics, Inc.
Via GlobeNewswire
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
October 28, 2024
From C4 Therapeutics, Inc.
Via GlobeNewswire
C4 Therapeutics Appoints Paige Mahaney, Ph.D., as Chief Scientific Officer and Announces Retirement of Stewart Fisher, Ph.D.
October 15, 2024
From C4 Therapeutics, Inc.
Via GlobeNewswire
C4 Therapeutics Announces Presentations and Participation in 7th Annual Targeted Protein Degradation & Induced Proximity Summit
October 09, 2024
From C4 Therapeutics, Inc.
Via GlobeNewswire
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
September 30, 2024
From C4 Therapeutics, Inc.
Via GlobeNewswire
C4 Therapeutics Presents Monotherapy Data Demonstrating Proof of Mechanism and Early Evidence of Proof of Concept From Ongoing CFT1946 Phase 1 Trial in BRAF V600 Mutant Solid Tumors at the European Society for Medical Oncology (ESMO) Congress 2024
September 13, 2024
From C4 Therapeutics, Inc.
Via GlobeNewswire
C4 Therapeutics Announces Delivery of Second Development Candidate to Biogen
September 10, 2024
From C4 Therapeutics, Inc.
Via GlobeNewswire
Methanex, Merck And Other Big Stocks Moving Lower In Monday's Pre-Market Session
September 09, 2024
Via Benzinga
Why Summit Therapeutics Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
September 09, 2024
Via Benzinga
C4 Therapeutics to Present Preliminary CFT1946 Monotherapy Phase 1 Clinical Data at the European Society for Medical Oncology (ESMO) Congress 2024
September 08, 2024
From C4 Therapeutics, Inc.
Via GlobeNewswire
C4 Therapeutics Appoints Veteran Biotechnology Leader Stephen Fawell, Ph.D. to Board of Directors
September 03, 2024
From C4 Therapeutics, Inc.
Via GlobeNewswire
C4 Therapeutics to Participate in Upcoming September Investor Conferences
August 29, 2024
From C4 Therapeutics, Inc.
Via GlobeNewswire
C4 Therapeutics Announces European Society for Medical Oncology (ESMO) Changed the Previously Accepted CFT1946 Preliminary Phase 1 Abstract to a Proffered Paper Presentation
August 14, 2024
From C4 Therapeutics, Inc.
Via GlobeNewswire
CCCC Stock Earnings: C4 Therapeutics Beats EPS, Beats Revenue for Q2 2024
August 01, 2024
Via InvestorPlace
C4 Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
August 01, 2024
From C4 Therapeutics, Inc.
Via GlobeNewswire
C4 Therapeutics to Present Preliminary Monotherapy Data from the Ongoing Phase 1 Trial of CFT1946 as a Mini Oral Presentation at the ESMO Congress 2024
July 16, 2024
From C4 Therapeutics, Inc.
Via GlobeNewswire
C4 Therapeutics to Participate in the Virtual UBS Targeted Protein Degradation Day
July 08, 2024
From C4 Therapeutics, Inc.
Via GlobeNewswire
C4 Therapeutics Appoints Ron Cooper as Chairman of the Board of Directors
June 10, 2024
From C4 Therapeutics, Inc.
Via GlobeNewswire
CCCC Stock Earnings: C4 Therapeutics Misses EPS, Misses Revenue for Q1 2024
May 08, 2024
Via InvestorPlace
Site Logo
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap